Skip to main content
. 2023 Apr 29;12(9):e028739. doi: 10.1161/JAHA.122.028739

Figure 2. Secondary end points (A, kidney‐specific composite; B, composite of HHF or cardiovascular death; and C, all‐cause death) by cardiovascular medication use/nonuse at baseline.

Figure 2

Kidney‐specific composite end point: ≥50% decline in eGFR, end‐stage kidney disease, or death from a kidney cause. ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; and HHF, hospitalization for heart failure; NC, not calculable.